- Home
- ATON vs INTS Comparison
ATON vs INTS Comparison
Compare ATON & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATON
- INTS
- Stock Information
- Founded
- ATON 1973
- INTS 2012
- Country
- ATON British Virgin Islands
- INTS United States
- Employees
- ATON N/A
- INTS N/A
- Industry
- ATON Oil & Gas Production
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- ATON Energy
- INTS Health Care
- Exchange
- ATON Nasdaq
- INTS Nasdaq
- Market Cap
- ATON 13.4M
- INTS 10.9M
- IPO Year
- ATON N/A
- INTS 2023
- Fundamental
- Price
- ATON N/A
- INTS $0.24
- Analyst Decision
- ATON
- INTS Strong Buy
- Analyst Count
- ATON 0
- INTS 4
- Target Price
- ATON N/A
- INTS $4.50
- AVG Volume (30 Days)
- ATON 86.9K
- INTS 4.2M
- Earning Date
- ATON 09-26-2025
- INTS 11-12-2025
- Dividend Yield
- ATON N/A
- INTS N/A
- EPS Growth
- ATON N/A
- INTS N/A
- EPS
- ATON N/A
- INTS N/A
- Revenue
- ATON N/A
- INTS N/A
- Revenue This Year
- ATON N/A
- INTS N/A
- Revenue Next Year
- ATON N/A
- INTS N/A
- P/E Ratio
- ATON N/A
- INTS N/A
- Revenue Growth
- ATON N/A
- INTS N/A
- 52 Week Low
- ATON $2.95
- INTS $0.19
- 52 Week High
- ATON $23.01
- INTS $4.25
- Technical
- Relative Strength Index (RSI)
- ATON N/A
- INTS 34.71
- Support Level
- ATON N/A
- INTS $0.27
- Resistance Level
- ATON N/A
- INTS $0.30
- Average True Range (ATR)
- ATON 0.00
- INTS 0.02
- MACD
- ATON 0.00
- INTS -0.01
- Stochastic Oscillator
- ATON 0.00
- INTS 19.22
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.